← Back to Clinical Trials
Recruiting NCT06959342

NCT06959342 Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06959342
Status Recruiting
Phase
Sponsor Central Institute of Mental Health, Mannheim
Condition Alcohol Use Disorder
Study Type INTERVENTIONAL
Enrollment 162 participants
Start Date 2024-09-23
Primary Completion 2027-03-31

Trial Parameters

Condition Alcohol Use Disorder
Sponsor Central Institute of Mental Health, Mannheim
Study Type INTERVENTIONAL
Phase N/A
Enrollment 162
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2024-09-23
Completion 2027-03-31
Interventions
Transcranial direct current stimulation (tDCS)Inhibition Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this project is to investigate the potential of transcranial direct current stimulation (tDCS) to reduce cognitive deficits and substance craving in individuals with substance use disorders (SUD), with a focus on alcohol use disorder (AUD). Patients of any gender between the ages of 18 and 65 are examined who are in our inpatient and day clinic settings for a standard detoxification treatment program. As there are conflicting findings regarding the effective settings for tDCS as an adjunctive treatment in SUD (e.g., effects on inhibitory control seem to be sensitive to current direction), the aim is to examine and compare three different active tDCS conditions, a sham tDCS condition (placebo), inhibition training, and a control group of patients receiving only standard detoxification treatment. The aim is to identify the optimal electrode placement and current direction to positively influence both inhibitory control and craving, leading to improved treatment outcomes such as longer abstinence periods or reduced substance use after relapse.

Eligibility Criteria

Inclusion Criteria: * main diagnosis: alcohol use disorder according to DSM-5 * patients of any gender aged 18 to 65 * normal vision or correctable visual impairment. * sufficient ability to communicate verbally and in writing * ability to give fully informed consent after reviewing thorough written information Exclusion Criteria: * withdrawal of consent * severe internal, neurological, or psychiatric comorbidities (e.g., lifetime schizophrenia, bipolar disorder, or other severe mental disorders according to ICD-10 and DSM-5, such as severe depression or PTSD within the last 12 months). * Exclusion criteria for an EEG/tDCS examination (e.g. metal implants in the head, epilepsy, etc.) * severe withdrawal symptoms (CIWA-R \> 7) * alcohol intoxication (breath alcohol concentration \> 0 ‰) * Pharmacotherapy with psychoactive substances within the last 14 days (exceptions: clomethiazole or benzodiazepines used in withdrawal treatment, provided they were discontinued at least 3 days prior; a

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology